// App-Quantinova.ai

435 : Prognostic biomarkers as molecular targets for individualized neoadjuvant treatment for cervical cancer

Researchers

Presenter

  • Pablo Moreno-Acosta

Principal Investigators

  • Oscar Gamboa

  • Diana Mayorga

  • Alfredo Romero

  • Jinneth Acosta

  • Maria Carolina Sanabria

  • Martha Cotes Mestre

  • Nicolas Magne

Medical Centers

  • National Cancer Institute, Bogota, D.C., Colombia

  • National University of Colombia, Bogota, D.C., Colombia

  • Institut de Cancerologie Lucien Neuwirth, Saint-Priest en Jarez cedex, France.

Locations

  • France

  • Colombia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Oral cancer

  • Cervical cancer

  • Solid malignancies

Biomarkers

  • Carbonic anhydrase IX

  • Cyclooxygenase-2

  • Epidermal growth factor receptor

  • Glucose transporter 1

  • Hypoxia-inducible factor-1

  • Insulin-like growth factor 1 receptor

  • Serine/threonine-protein kinase mTOR

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Prospective

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved